BioSpace News Archive

Business

Report: Investors Urge Ouster of Regeneron Director Over Executive Compensation

Two of the company’s largest shareholders call for the ouster of a company director at Regeneron as top executives are under fire for their enormous compensation packages.

June 10, 2021
·
2 min read
·
Alex Keown
Business

Three Biopharma Companies Close Series A Financing Rounds

June appears to be a busy month for Series A financing rounds, with Kurome, Onchilles Pharma, and Hawthorne Effect closing in on millions of dollars worth of startup investments.

June 10, 2021
·
3 min read
·
Brandon May
Drug Development

Ocugen Faces Major Slowdown for COVID-19 Vaccine as FDA Recommends BLA

The Pennsylvania-based eye disease company had to change its application from an Emergency Use Authorization to a full BLA approval.

June 10, 2021
·
2 min read
·
Kate Goodwin
Genetown

Seres Bolsters Rationale Behind GVHD, Cancer Programs at ASCO Meeting

With an oral presentation and a poster at the ASCO Annual Meeting this year, Seres Therapeutics sought to bolster the case for two of its microbiome therapeutics programs.

June 10, 2021
·
4 min read
·
Mark Zipkin
Career Advice

The Art of Drafting a Perfect Cover Letter in 2021

If you’re considering preparing for your next interview, know that you need to learn the art of drafting a perfect cover letter to show that you’re a great match for the position.

June 10, 2021
·
2 min read
·
Brandi Marcene
Drug Development

COVID-19 News Update: Moderna Files for EUA in Adolescents and More

Although the COVID-19 pandemic is waning in the U.S., there is still plenty of research and news about the disease. Here’s a look.

June 10, 2021
·
5 min read
·
Mark Terry
Drug Development

Are Vindictive Variants Threatening Our COVID-19 Recovery?

According to the CDC, the Delta variant now accounts for more than 6% of infections in the U.S. and may be responsible for 18% of cases in some Western states.

June 10, 2021
·
5 min read
·
Heather McKenzie
Drug Development

OXURION Confirms Institutional Review Board Approval and Submission of the Investigational New Drug Application to the FDA to Start Phase 2 Study Evaluating THR-687 for Diabetic Macular Edema (DME)

Oxurion NV announces that it has received Institutional Review Board approval to initiate a Phase 2 clinical study of THR-687 in patients with Diabetic Macular Edema.

June 10, 2021
·
5 min read
Business

GenSight Biologics Appoints Marion Ghibaudo as Chief Technical Officer to Lead GS030 Device Engineering

GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced the appointment of Marion Ghibaudo as Chief Technical Officer.

June 10, 2021
·
6 min read
Business

Confo Therapeutics Establishes Medical Advisory Board

Confo Therapeutics announced the establishment of its Medical Advisory Board. The MAB will provide external review and strategic advice for the company’s clinical development program including the future direction of CFTX-1554, Confo’s lead pre-clinical candidate in neuropathic pain.

June 10, 2021
·
5 min read